tablets Epletor are shown as:

• Addition to standard treatment using β-blockers for the purpose of the reduction of risk of incidence and lethality connected with cardiovascular diseases at stable patients with dysfunction of a left ventricle (fraction of emission of a left ventricle ≤ 40%) and clinical signs of heart failure after recently postponed myocardial infarction.
• Addition to standard optimum therapy for the purpose of reduction of risk of the incidence and lethality connected with cardiovascular diseases at adult patients with heart failure of the II class (chronic) on classification by NYHA and dysfunction of a left ventricle (fraction of emission of a left ventricle ≤ 30%).

Structure

Active ingredient: eplerenon;

1 tablet contains 25 mg or 50 mg of an eplerenon (in terms of 100% anhydrous substance);

Excipients: lactoses monohydrate, cellulose microcrystalline, sodium of a kroskarmeloz, gipromeloz, sodium lauryl sulfate, talc, magnesium stearate;

Film covering: Opadry yellow 15 B220000 (gipromeloza, polysorbate 80, macrogoal (PEG 400), titan dioxide (E 171), ferrous oxide yellow (E 172)).

Contraindication

• hypersensitivity to an eplerenon or to ohm to a medicament component;
• clinically significant hyperpotassemia or the related states (potassium level in blood serum more than 5 mmol/l (mekv/l)) on an initiation of treatment;
• heavy degree of a renal failure (rated speed of glomerular filtration <30 ml/min. / 1.73 m ² );
• a heavy liver failure (class C on Chayld-Pyyu);
• simultaneous use with other kaliysberegayushchy diuretics, potassium medicaments / kaliysoderzhashchimi additives or such powerful CYP3A4 inhibitors, as ketokonazol, itrakonazol, ritonavir, nelfinavir, klaritromitsin, telitromitsin, nefazodon;
• triple combination of APF inhibitors, blockers of receptors of angiotensin (BRA) and eplerenona.

Route of administration

For individual selection of a dosage medicament exists in doses of 25 mg and 50 mg. The maximum daily dose makes 50 mg a day.

Eplerenon can be applied both with food, and irrespective of meal.

Feature of use

by

eplerenon to pregnant women with care. Children

it is not recommended to p to apply

.

Drivers

With care.

Overdose

About cases of overdose of an eplerenon of messages did not arrive. Arterial hypotension and/or a hyperpotassemia can be the most probable signs of overdose.

Eplerenon substantially contacts activated carbon. Drug is not removed by a hemodialysis.

At emergence of symptoms of overdose standard symptomatic and maintenance therapy.

Side effects

• Infection and invasion: infection, pyelonephritis, pharyngitis.
• System of blood and lymphatic system: eosinophilia.
• Endocrine system: hypothyroidism.
• Metabolic disorders and disturbances of a trophicity: hyperpotassemia, hyponatremia, dehydration, hypercholesterolemia, gipertriglitseridemiya, dislipidemiya.
• Mental disturbances: insomnia.
• Nervous system: dizziness, syncope, headache, hypesthesia.
• Cardiovascular system: arterial hypotension, fibrillation of auricles, left ventricular heart failure, tachycardia, postural hypotension, arterial fibrinferments of extremities.
• Respiratory system: cough.
• Digestive tract: diarrhea, nausea, constipation, vomiting, meteorism.
• Gepatobiliarnaya system: cholecystitis.
• Skin and hypodermic cellulose: rash, an itching, the increased perspiration, there were messages about cases of a Quincke's disease.
• Musculoskeletal system and connective tissue: muscular spasms, musculoskeletal pains, dorsodynia.
• Urinary system: renal failures, increase in levels of urea, creatinine in blood serum.
• Reproductive system and mammary glands: gynecomastia.
• General disorders: asthenia, feeling of an indisposition.
• Another: decrease in level of receptors of an epidermal growth factor, increase in level of glucose of blood.

during the research of active ingredient eplerenon (EPHESUS) at patients at the age of 75 years registered stroke cases.

Interaction

use of kaliysberegayushchy diuretics or powerful CYP inhibitors 3A4 (for example, itrakonazol, ketokonazol, ritonavir, nelfinavir, klaritromitsin, telitromitsin and nefazodon).

Contraindicated simultaneous use of an eplerenon in a triple combination together with APF inhibitor and blockers of receptors of angiotensin.

Storage conditions

In original packing at a temperature not above 25 °C.

out of children's reach.

Expiration date - 3 years.